WO1998042324A3 - Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors - Google Patents
Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors Download PDFInfo
- Publication number
- WO1998042324A3 WO1998042324A3 PCT/US1998/005623 US9805623W WO9842324A3 WO 1998042324 A3 WO1998042324 A3 WO 1998042324A3 US 9805623 W US9805623 W US 9805623W WO 9842324 A3 WO9842324 A3 WO 9842324A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reductase inhibitors
- methods
- aldose reductase
- neurotrophic factor
- associated activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU64738/98A AU6473898A (en) | 1997-03-21 | 1998-03-23 | Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82210397A | 1997-03-21 | 1997-03-21 | |
US08/822,103 | 1997-03-21 | ||
US09/045,194 US6696407B1 (en) | 1997-03-21 | 1998-03-20 | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
US09/045,194 | 1998-03-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998042324A2 WO1998042324A2 (en) | 1998-10-01 |
WO1998042324A3 true WO1998042324A3 (en) | 1999-01-21 |
WO1998042324A9 WO1998042324A9 (en) | 1999-03-18 |
Family
ID=26722480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/005623 WO1998042324A2 (en) | 1997-03-21 | 1998-03-23 | Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6473898A (en) |
WO (1) | WO1998042324A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0002895A1 (en) * | 1977-12-29 | 1979-07-11 | Imperial Chemical Industries Plc | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture |
EP0059596A1 (en) * | 1981-03-02 | 1982-09-08 | Ayerst, Mckenna And Harrison Inc. | N-Naphthoylglycine derivatives |
WO1992016544A1 (en) * | 1991-03-21 | 1992-10-01 | Parfums Christian Dior | Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it |
-
1998
- 1998-03-23 AU AU64738/98A patent/AU6473898A/en not_active Abandoned
- 1998-03-23 WO PCT/US1998/005623 patent/WO1998042324A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0002895A1 (en) * | 1977-12-29 | 1979-07-11 | Imperial Chemical Industries Plc | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture |
EP0059596A1 (en) * | 1981-03-02 | 1982-09-08 | Ayerst, Mckenna And Harrison Inc. | N-Naphthoylglycine derivatives |
WO1992016544A1 (en) * | 1991-03-21 | 1992-10-01 | Parfums Christian Dior | Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it |
Non-Patent Citations (10)
Title |
---|
A.A.F. SIMA ET AL.: "PREVENTIVE EFFECT OF LONG-TERM ALDOSE REDUCTASE INHIBITION (PONALRESTAT) ON NERVE CONDUCTION AND SURAL NERVE STRUCTURE IN THE SPONTANEOUSLY DIABETIC BIO-BREEDING RAT", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 85, no. 5, 1990, pages 1410 - 1420, XP002081353 * |
A.P. MIZISIN ET AL.: "ALDOSE REDUCTASE INHIBITION INCREASES CNTF-LIKE BIOACTIVITY AND PROTEIN IN SCIATIC NERVES FROM GALACTOSE-FED AND NORMAL RATS", DIABETES, vol. 46, no. 4, April 1997 (1997-04-01), pages 647 - 652, XP002081349 * |
A.P. MIZISIN ET AL.: "SCHWANN CELL INJURY IS ATTENUATED BY ALDOSE REDUCTASE INHIBITION IN GALACTOSE INTOXICATION", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 52, no. 1, 1993, pages 78 - 86, XP002081350 * |
D.A. GREENE ET AL.: "EFFECTS OF ALDOSE REDUCTASE INHIBITORS ON THE PROGRESSION OF NERVE DAMAGE", DIABETIC MEDICINE, vol. 10, no. S2, 1993, pages 31S - 32S, XP002081352 * |
D.F. EMERICH ET AL.: "IMPLANTS OF ENCAPSULATED HUMAN CNTF-PRODUCING FIBROBLASTS PREVENT BEHAVIORAL DEFICIT AND STRIATAL DEGENERATION IN A RODENT MODEL OF HUNTINGTON'S DISEASE", THE JOURNAL OF NEUROSCIENCE, vol. 16, no. 16, 1996, pages 5168 - 5181, XP002081356 * |
D.R. TOMLINSON ET AL.: "ALDOSE REDUCTASE INHIBITORS AND DIABETIC COMPLICATIONS", PHARMACOLOGY & THERAPEUTICS, vol. 54, no. 2, 1992, pages 151 - 194, XP002081358 * |
F. DITTRICH ET AL.: "CILIARY NEUROTROPHIC FACTOR: PHARMACOKINETICS AND ACUTE-PHASE RESPONSE IN RAT", ANNALS OF NEUROLOGY, vol. 35, no. 2, 1994, pages 151 - 163, XP002081357 * |
J.B. JASPAN ET AL.: "CLINICAL STUDIES WITH AN ALDOSE REDUCTASE INHIBITOR IN THE AUTONOMIC AND SOMATIC NEUROPATHIES OF DIABETES", METABOLISM, vol. 35, no. 4, 1986, pages 83 - 92, XP002081354 * |
M. TERADA ET AL.: "TOLRESTAT IMPROVES NERVE REGENERATION AFTER CRUSH INJURY IN STREPTOZOCIN-INDUCED DIABETIC RATS", METABOLISM, vol. 45, no. 10, pages 1189 - 1195, XP002081351 * |
N.A. CALCUTT ET AL.: "REDUCED CILIARY NEURONOTROPHIC FACTOR-LIKE ACTIVITY IN NERVES FROM DIABETIC OR GALACTOSE-FED RATS", BRAIN RESEARCH, vol. 575, no. 2, 1992, pages 320 - 324, XP002081355 * |
Also Published As
Publication number | Publication date |
---|---|
AU6473898A (en) | 1998-10-20 |
WO1998042324A2 (en) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998040055A3 (en) | Anti-epileptogenic agents | |
EP1247803A3 (en) | Indolinone compounds suitable for modulation of protein kinases | |
AU2001288628A1 (en) | Method and reagents for treatment of skin disorders by modulating the notch pathway | |
WO2002069900A3 (en) | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors | |
AU7538398A (en) | Emulsion for well and formation treatment | |
WO2003002717A3 (en) | Biological activity of ak155 | |
AU5801199A (en) | Bottom or top jumpered foldable electronic assembly, and method for manufacture | |
WO2002098899A3 (en) | CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE | |
WO2001085093A3 (en) | Compounds and methods for modulating cerebral amyloid angiopathy | |
WO2001006989A3 (en) | Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders | |
WO2004028454A3 (en) | 1, 3, 5-triazines for treatment of viral diseases | |
EP1400523A3 (en) | Intermediate compounds | |
AU2396000A (en) | Treatment of hyperproliferative disorders using casein kinase | |
WO1999025843A3 (en) | Human checkpoint kinase, hcds1, compositions and methods | |
WO1999019513A3 (en) | Methods for detecting compounds which modulate the activity of an lpa receptor | |
WO2001098279A3 (en) | Bis-arylsulfones | |
ZA200203253B (en) | Methods and kits for treating depression or preventing deterioration of cognitive function. | |
WO2002083651A3 (en) | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | |
WO2002073208A3 (en) | Anti-epileptogenic agents | |
WO2003010291A3 (en) | Treatment of immune disorders and b cell disorders | |
WO2000006083A3 (en) | Sulfonamide derivatives | |
WO2002079474A3 (en) | Human b7 polypeptides | |
WO2001016377A3 (en) | Diagnostics and therapeutics for osteoporosis | |
EP1012150A4 (en) | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | |
ZA9811537B (en) | Methods for regulating phagocytosis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998545863 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |